The Role of Sodium-Glucose Cotransporter 2 Inhibitors on Peripheral Nerves and Skeletal Muscle Function in Type 2 Diabetes
Abstract
Introduction: Diabetes is one of the four main non-communicable diseases in Sri Lanka with prevalence of 26%. SGLT2 inhibitors, primarily used for glycaemic control in type 2 diabetes, have recently garnered attention for their potential effects on neuromuscular function. The primary objective of this scoping review was to map the existing literature to determine the extent, range and nature of published evidence on the effects of SGLT2 inhibitors on peripheral nerve morphology, electrophysiology and skeletal muscle function and metabolic kinetics.
Methodology: Guided by the PRISMA extension for Scoping Reviews (PRISMA-ScR), an electronic search was executed across PubMed, ScienceDirect and Google Scholar for literature published from 2010 onwards. Applying a strict Population-Concept-Context (PCC) framework, two independent reviewers screened and analyzed studies evaluating human populations or corresponding animal models with T2DM (Population) undergoing SGLT2 inhibitor therapy (Concept), in relation to somatic/autonomic nerve conduction, nerve histology, muscle mass and metabolic processing (Context). Data extraction charted study characteristics, species, specific drug types, duration of effect and symptom relief versus electrophysiological outcomes.
Results: Thirty-two studies met the inclusion criteria with 16 evaluating peripheral nerves and 16 focusing on skeletal muscle kinetics. Evidence from animal models and human trials suggests potential improvements in…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.